Skip to main content
. Author manuscript; available in PMC: 2020 Apr 28.
Published in final edited form as: Cancer Causes Control. 2020 Jan 16;31(3):221–230. doi: 10.1007/s10552-019-01265-0

Table 1.

Distribution and odds ratios with 95% confidence intervals of latent classes, Carolina Breast Cancer Study 3 (2008-2013) by age and racea

Race and age, y
White
Black
All cases
(n=2998)
<50
(n=751)
≥50
(n=752)
<50
(n=741)
≥50
(n=754)
No. (%) No. (%) No. (%) No. (%) No. (%)
SES/Comorbidity latent classes
   Low SES/High comorbidity 1428 (47.6) 134 (9.4) 259 (18.1) 455 (31.9) 580 (40.6)
   High SES/Low comorbidity 1570 (52.4) 617 (39.3) 493 (31.4) 286 (18.2) 174 (11.1)
 Low vs. high, OR (95% CI) 0.5 (0.4-0.6) 1.0 ref 3.2 (2.5-4.1) 6.2 (4.7-8.1)
Access to care latent classes
   Less barriers to care 2514 (84.1) 709 (28.2) 737 (29.3) 482 (19.2) 574 (22.8)
   More barriers to care 476 (15.9) 42 (8.8) 15 (3.2) 258 (54.2) 180 (37.8)
 Less vs. more, OR (95% CI) 3.3 (1.6-6.4) 1.0 ref 15.3 (7.8-29.9) 7.8 (4.1-15.4)
Tumor Characteristics latent classesb
   HR+/HER2−/Node Negative 1091 (36.5) 290 (26.6) 419 (38.4) 117 (10.7) 265 (24.3)
   HER2+/Higher Grade 335 (11.2) 86 (25.7) 59 (17.6) 99 (29.5) 91 (27.2)
   HR+/HER2−/Larger Tumor/Node Positive 944 (31.6) 259 (27.4) 181 (19.2) 301 (31.9) 203 (21.5)
   TNBC/Higher Grade 617 (20.7) 115 (18.6) 90 (14.6) 222 (36.0) 190 (30.8)
 HER2+ vs. HR+/HER2−/Node−, OR (95% CI) 2.6 (1.9-3.6) 1.0 ref 6.3 (4.3-9.1) 2.0 (1.4-2.8)
 HR+ vs. HR+/HER2−/Node−, OR (95% CI) 2.3 (1.5-3.6) 1.0 ref 6.3 (3.9-10.0) 2.6 (2.5-3.8)
 TNBC vs. HR+/HER2−/Node -, OR (95% CI) 2.0 (1.5-2.9) 1.0 ref 9.0 (6.1-13.0) 3.4 (2.5-4.6)

Abbreviations: SES, socioeconomic status; HER2+, human epidermal growth factor receptor 2 positive; TNBC, triple negative breast cancer

a

Latent class domains not mutually adjusting for one another

b

N=2987